Gianpietro C Semenzato

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5296757/publications.pdf

Version: 2024-02-01

440 papers	17,694 citations	15504 65 h-index	25787 108 g-index
448 all docs	448 docs citations	448 times ranked	14934 citing authors

#	Article	IF	Citations
1	The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation. Haematologica, 2022, 107, 868-876.	3.5	31
2	Identification of novel STAT5B mutations and characterization of TCRÎ² signatures in CD4+ T-cell large granular lymphocyte leukemia. Blood Cancer Journal, 2022, 12, 31.	6.2	15
3	Interrogating molecular genetics to refine LGLL classification. Blood, 2022, 139, 3002-3004.	1.4	6
4	Hypocellular myelodysplastic syndromes (h-MDS): from clinical description to immunological characterization in the Italian multi-center experience. Leukemia, 2022, 36, 1947-1950.	7.2	9
5	Defining TCRÎ³Î´ lymphoproliferative disorders by combined immunophenotypic and molecular evaluation. Nature Communications, 2022, 13, .	12.8	7
6	Enhanced IL-9 secretion by p66Shc-deficient CLL cells modulates the chemokine landscape of the stromal microenvironment. Blood, 2021, 137, 2182-2195.	1.4	7
7	Second primary malignancy in myelofibrosis patients treated with ruxolitinib. British Journal of Haematology, 2021, 193, 356-368.	2.5	19
8	Large Granular Lymphocyte Leukemia. Hematologic Malignancies, 2021, , 231-246.	0.2	0
9	The Importance of Alliance between Hematologists and Dentists: A Retrospective Study on the Development of Bisphosphonates Osteonecrosis of the Jaws (Bronj) in Multiple Myeloma Patients. Dentistry Journal, 2021, 9, 11.	2.3	3
10	Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis. Blood Cancer Journal, 2021, 11, 4.	6.2	41
11	Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome. Cancer, 2021, 127, 2657-2665.	4.1	14
12	GSK-3 Inhibition Modulates Metalloproteases in a Model of Lung Inflammation and Fibrosis. Frontiers in Molecular Biosciences, 2021, 8, 633054.	3.5	10
13	Serum Anti-Heart and Anti-Intercalated Disk Autoantibodies: Novel Autoimmune Markers in Cardiac Sarcoidosis. Journal of Clinical Medicine, 2021, 10, 2476.	2.4	9
14	Neutropenia and Large Granular Lymphocyte Leukemia: From Pathogenesis to Therapeutic Options. Cells, 2021, 10, 2800.	4.1	16
15	Protein Kinase CK1Î± Sustains B-Cell Receptor Signaling in Mantle Cell Lymphoma. Frontiers in Oncology, 2021, 11, 733848.	2.8	4
16	Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Cancer, 2020, 126, 1243-1252.	4.1	106
17	Stat3 mutations impact on overall survival in large granular lymphocyte leukemia: a single-center experience of 205 patients. Leukemia, 2020, 34, 1116-1124.	7.2	49
18	New responsibilities for aged kinases in Bâ€lymphomas. Hematological Oncology, 2020, 38, 3-11.	1.7	8

#	Article	IF	Citations
19	Insight into the mechanism of cytotoxicity of membrane-permeant psoralenic Kv1.3 channel inhibitors by chemical dissection of a novel member of the family. Redox Biology, 2020, 37, 101705.	9.0	22
20	Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia . OncoTargets and Therapy, 2020, Volume 13, 9679-9688.	2.0	19
21	Ibrutinib in relapsed hairy cell leukemia variant: A case report and review of the literature. Hematological Oncology, 2020, 38, 823-826.	1.7	16
22	A case of â€œdouble hitâ€•mantle cell lymphoma carrying CCND1 and MYC translocations relapsed/refractory to rituximab bendamustine cytarabine (R-BAC) and ibrutinib. Annals of Hematology, 2020, 99, 2715-2717.	1.8	2
23	Identification of a miR-146b-Fas ligand axis in the development of neutropenia in T large granular lymphocyte leukemia. Haematologica, 2020, 105, 1351-1360.	3.5	28
24	Actionable Strategies to Target Multiple Myeloma Plasma Cell Resistance/Resilience to Stress: Insights From â€œOmicsâ€•Research. Frontiers in Oncology, 2020, 10, 802.	2.8	3
25	Insights Into Genetic Landscape of Large Granular Lymphocyte Leukemia. Frontiers in Oncology, 2020, 10, 152.	2.8	40
26	A Noninterventional, Observational, European Post-Authorization Safety Study of Patients With Relapsed/Refractory Multiple Myeloma Treated With Lenalidomide. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e629-e644.	0.4	1
27	NK cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias. Cells, 2020, 9, 768.	4.1	27
28	Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Realâ€•world data. Hematological Oncology, 2020, 38, 372-380.	1.7	15
29	A high definition picture of somatic mutations in chronic lymphoproliferative disorder of natural killer cells. Blood Cancer Journal, 2020, 10, 42.	6.2	22
30	Lack of Viral Load Within Chronic Lymphoproliferative Disorder of Natural Killer Cells: What Is Outside the Leukemic Clone?. Frontiers in Oncology, 2020, 10, 613570.	2.8	3
31	Clinical Characteristics and Outcome of West Nile Virus Infection in Patients with Lymphoid Neoplasms: An Italian Multicentre Study. HemaSphere, 2020, 4, e395.	2.7	4
32	Retrospective Real-Life Comparison of Obinutuzumab Plus Chlorambucil Versus Ibrutinib in Previously Untreated and Unfit Patients with Chronic Lymphocytic Leukemia without TP53 Disruptions. Interim Results from the Italian CLL Campus. Blood, 2020, 136, 30-31.	1.4	0
33	Complex Karyotype Subtypes at Chronic Lymphocytic Leukemia Diagnosis Refine the Risk of Developing a Richter Syndrome. the Richter Syndrome Scoring System. Blood, 2020, 136, 33-34.	1.4	1
34	Ruxolitinib Rechallenge in Resistant/Intolerant MF Patients: Frequency, Therapeutic Effects, and Impact on Outcome. Blood, 2020, 136, 49-50.	1.4	0
35	BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome. British Journal of Haematology, 2019, 185, 193-197.	2.5	24
36	Prosurvival autophagy is regulated by protein kinase CK1 alpha in multiple myeloma. Cell Death Discovery, 2019, 5, 98.	4.7	22

#	Article	IF	Citations
37	A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia. Hematological Oncology, 2019, 37, 508-512.	1.7	13
38	Bortezomib-based regimens in patients with POEMS syndrome: a case series in newly diagnosed and relapsed patients. Leukemia and Lymphoma, 2019, 60, 2067-2070.	1.3	13
39	The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia. British Journal of Cancer, 2019, 121, 150-156.	6.4	31
40	T cell large granular lymphocyte leukemia and chronic NK lymphocytosis. Best Practice and Research in Clinical Haematology, 2019, 32, 207-216.	1.7	37
41	HSP70/HSF1 axis, regulated via a PI3K/AKT pathway, is a druggable target in chronic lymphocytic leukemia. International Journal of Cancer, 2019, 145, 3089-3100.	5.1	32
42	Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 678-685.e4.	0.4	25
43	p66Shc deficiency in the Eî¼-TCL1 mouse model of chronic lymphocytic leukemia enhances leukemogenesis by altering the chemokine receptor landscape. Haematologica, 2019, 104, 2040-2052.	3.5	17
44	In Chronic Lymphocytic Leukemia the JAK2/STAT3 Pathway Is Constitutively Activated and Its Inhibition Leads to CLL Cell Death Unaffected by the Protective Bone Marrow Microenvironment. Cancers, 2019, 11, 1939.	3.7	39
45	Cortactin expression in non-Hodgkin B-cell lymphomas: a new marker for the differential diagnosis between chronic lymphocytic leukemia and mantle cell lymphoma. Human Pathology, 2019, 85, 251-259.	2.0	6
46	Mitochondrial apoptosis is induced by Alkoxy phenyl-1-propanone derivatives through PP2A-mediated dephosphorylation of Bad and Foxo3A in CLL. Leukemia, 2019, 33, 1148-1160.	7.2	25
47	Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib. Annals of Hematology, 2019, 98, 889-896.	1.8	10
48	In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics. British Journal of Haematology, 2018, 181, 229-233.	2.5	34
49	The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma. Blood Cancer Journal, 2018, 8, 20.	6.2	19
50	p66Shc deficiency enhances CXCR4 and CCR7 recycling in CLL B cells by facilitating their dephosphorylation-dependent release from Î²-arrestin at early endosomes. Oncogene, 2018, 37, 1534-1550.	5.9	23
51	Idelalisib plus rituximab is effective in systemic AL amyloidosis secondary to chronic lymphocytic leukaemia. Hematological Oncology, 2018, 36, 366-369.	1.7	6
52	Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients. Leukemia Research, 2018, 74, 86-88.	0.8	23
53	Benign TdT-positive cells in pediatric and adult lymph nodes: a potential diagnostic pitfall. Human Pathology, 2018, 81, 131-137.	2.0	6
54	Dominant cytotoxic NK cell subset within CLPD-NK patients identifies a more aggressive NK cell proliferation. Blood Cancer Journal, 2018, 8, 51.	6.2	20

#	Article	IF	Citations
55	Possible neuroleukemiosis in two patients with acute myeloid leukemia in complete bone marrow remission. Journal of the Neurological Sciences, 2018, 392, 63-64.	0.6	4
56	Old and Young Actors Playing Novel Roles in the Drama of Multiple Myeloma Bone Marrow Microenvironment Dependent Drug Resistance. International Journal of Molecular Sciences, 2018, 19, 1512.	4.1	16
57	Splenic marginal zone lymphoma with a de novo t(8;14)(q24;q32) and a prolymphocytoid evolution responsive to rituximab-bendamustine. Annals of Hematology, 2018, 97, 2001-2003.	1.8	0
58	Dabigatran in ibrutinibâ€treated patients with atrial fibrillation and lymphoproliferative diseases: Experience of 4 cases. Hematological Oncology, 2018, 36, 801-803.	1.7	4
59	Efficacy and Safety of Ibrutinib (IBR) after Venetoclax (VEN) Treatment in IBR-NaÃ¯ve Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Follow-up of Patients from the MURANO Study. Blood, 2018, 132, 5548-5548.	1.4	9
60	Abnormal regulation of BCR signalling by c-Cbl in chronic lymphocytic leukaemia. Oncotarget, 2018, 9, 32219-32231.	1.8	6
61	CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death. Current Cancer Drug Targets, 2018, 18, 608-616.	1.6	10
62	Direct Pharmacological Targeting of a Mitochondrial Ion Channel Selectively Kills Tumor Cells InÂVivo. Cancer Cell, 2017, 31, 516-531.e10.	16.8	138
63	Role of miR-15a/miR-16-1 and the TP53 axis in regulating telomerase expression in chronic lymphocytic leukemia. Haematologica, 2017, 102, e253-e256.	3.5	13
64	Cortactin, a Lyn substrate, is a checkpoint molecule at the intersection of BCR and CXCR4 signalling pathway in chronic lymphocytic leukaemia cells. British Journal of Haematology, 2017, 178, 81-93.	2.5	25
65	Aberrant expression of <scp>CD</scp>10 and <scp>BCL</scp>6 in mantle cell lymphoma. Histopathology, 2017, 71, 769-777.	2.9	29
66	Major infections, secondary cancers and autoimmune diseases occur in different clinical subsets of chronic lymphocytic leukaemia patients. European Journal of Cancer, 2017, 72, 103-111.	2.8	29
67	Peripheral neuropathies in chronic lymphocytic leukemia: a single center experience on 816 patients. Haematologica, 2017, 102, e140-e143.	3.5	17
68	Integration of B-cell receptor-induced ERK1/2 phosphorylation and mutations of SF3B1 gene refines prognosis in treatment-naÃ¯ve chronic lymphocytic leukemia. Haematologica, 2017, 102, e144-e147.	3.5	4
69	Diagnostic and prognostic value of low percentage of glycosylated ferritin in acquired hemophagocytic lymphohistiocytosis: A singleâ€center study. International Journal of Laboratory Hematology, 2017, 39, 620-624.	1.3	16
70	Targeted activation of the SHP-1/PP2A signaling axis elicits apoptosis of chronic lymphocytic leukemia cells. Haematologica, 2017, 102, 1401-1412.	3.5	23
71	Protein kinase CK2 regulates AKT, NF-ÎºB and STAT3 activation, stem cell viability and proliferation in acute myeloid leukemia. Leukemia, 2017, 31, 292-300.	7.2	55
72	Epidemiology and risk factors of invasive fungal infections in a large cohort of patients with chronic lymphocytic leukemia. Hematological Oncology, 2017, 35, 925-928.	1.7	19

#	Article	IF	Citations
73	P160Three-dimensional left ventricular global longitudinal strain is as feasible and accurate as two-dimensional global longitudinal strain for subclinical cardiotoxicity surveillance. European Heart Journal, 2017, 38, .	2.2	0
74	Inactivation of CK1Î± in multiple myeloma empowers drug cytotoxicity by affecting AKT and Î²-catenin survival signaling pathways. Oncotarget, 2017, 8, 14604-14619.	1.8	30
75	STAT3 mutation impacts biological and clinical features of T-LGL leukemia. Oncotarget, 2017, 8, 61876-61889.	1.8	67
76	Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: a report of three cases. Oncotarget, 2017, 8, 110727-110731.	1.8	23
77	Multicentre survey to explore current survival of patients with acute myeloid leukaemia who failed induction chemotherapy. European Journal of Haematology, 2016, 96, 586-592.	2.2	3
78	Targeting CK2-driven non-oncogene addiction in B-cell tumors. Oncogene, 2016, 35, 6045-6052.	5.9	24
79	Profiling B cell chronic lymphocytic leukemia by reverse phase protein array: Focus on apoptotic proteins. Journal of Leukocyte Biology, 2016, 100, 1061-1070.	3.3	14
80	Evaluation of Integrated CLL Scoring System (ICSS) in 420 Patients with Chronic Lymphocytic Leukemia. Blood, 2016, 128, 5563-5563.	1.4	1
81	Expression of the p66Shc protein adaptor is regulated by the activator of transcription STAT4 in normal and chronic lymphocytic leukemia B cells. Oncotarget, 2016, 7, 57086-57098.	1.8	19
82	A Pyrazolo[3,4-d]pyrimidine compound inhibits Fyn phosphorylation and induces apoptosis in natural killer cell leukemia. Oncotarget, 2016, 7, 65171-65184.	1.8	18
83	The isopeptidase inhibitor 2cPE triggers proteotoxic stress and ATM activation in chronic lymphocytic leukemia cells. Oncotarget, 2016, 7, 45429-45443.	1.8	12
84	HSP70-HSF1 Interplays Has a Role in the Pathogenesis of Chronic Lymphocytic Leukemia and Is a Druggable Target. Blood, 2016, 128, 4368-4368.	1.4	0
85	Clinical profile associated with infections in patients with chronic lymphocytic leukemia. Protective role of immunoglobulin replacement therapy. Haematologica, 2015, 100, e515-e518.	3.5	48
86	Lyn sustains oncogenic signaling in chronic lymphocytic leukemia by strengthening SET-mediated inhibition of PP2A. Blood, 2015, 125, 3747-3755.	1.4	40
87	Early effects of the antineoplastic agent salinomycin on mitochondrial function. Cell Death and Disease, 2015, 6, e1930-e1930.	6.3	64
88	TL1A/DR3 axis involvement in the inflammatory cytokine network during pulmonary sarcoidosis. Clinical and Molecular Allergy, 2015, 13, 16.	1.8	21
89	Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival. Oncotarget, 2015, 6, 42130-42149.	1.8	39
90	Biophysical Characterization and Expression Analysis of Kv1.3 Potassium Channel in Primary Human Leukemic B Cells. Cellular Physiology and Biochemistry, 2015, 37, 965-978.	1.6	35

#	Article	IF	Citations
91	Differences among young adults, adults and elderly chronic myeloid leukemia patients. Annals of Oncology, 2015, 26, 185-192.	1.2	72
92	Integrated CLL Scoring System, a New and Simple Index to Predict Time to Treatment and Overall Survival in Patients With Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 612-620.e5.	0.4	26
93	Serum free light chains in the differential diagnosis and prognosis of primary and secondary hypogammaglobulinemia. Journal of Allergy and Clinical Immunology, 2015, 135, 1075-1077.e6.	2.9	12
94	Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy. American Journal of Hematology, 2015, 90, E135-E137.	4.1	1
95	Ex Vivo Signaling Protein Mapping in T Lymphocytes in the Psoriatic Arthritis Joints. Journal of rheumatology Supplement, The, 2015, 93, 48-52.	2.2	29
96	Cytogenetic Impact on Lenalidomide Treatment in Relapsed/Refractory Multiple Myeloma: A Real-Life Evaluation. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 592-598.	0.4	2
97	Enhanced Chemokine Receptor Recycling and Impaired S1P1 Expression Promote Leukemic Cell Infiltration of Lymph Nodes in Chronic Lymphocytic Leukemia. Cancer Research, 2015, 75, 4153-4163.	0.9	41
98	Transcriptional network profile on synovial fluid T cells in psoriatic arthritis. Clinical Rheumatology, 2015, 34, 1571-1580.	2.2	36
99	Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth. Oncotarget, 2015, 6, 6544-6552.	1.8	31
100	Cyclophosphamide as a first-line therapy in LGL leukemia. Leukemia, 2014, 28, 1134-1136.	7.2	74
101	Activating KIRs in Chronic Lymphoproliferative Disorder of NK Cells: Protection from Viruses and Disease Induction?. Frontiers in Immunology, 2014, 5, 72.	4.8	22
102	Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia. Haematologica, 2014, 99, 881-887.	3.5	32
103	Leukaemic cells from chronic lymphocytic leukaemia patients undergo apoptosis following microtubule depolymerization and <scp>L</scp>yn inhibition by nocodazole. British Journal of Haematology, 2014, 165, 659-672.	2.5	26
104	Bone marrow stromal cell-fueled multiple myeloma growth and osteoclastogenesis are sustained by protein kinase CK2. Leukemia, 2014, 28, 2094-2097.	7.2	14
105	Chronic natural killer lymphoproliferative disorders: characteristics of an international cohort of 70 patients. Annals of Oncology, 2014, 25, 2030-2035.	1.2	49
106	JAK/STAT/PKCÎ´ molecular pathways in synovial fluid T lymphocytes reflect the in vivo T helper-17 expansion in psoriatic arthritis. Immunologic Research, 2014, 58, 61-69.	2.9	65
107	Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients. Haematologica, 2014, 99, 1101-1106.	3.5	63
108	Lyn-mediated procaspase 8 dimerization blocks apoptotic signaling in B-cell chronic lymphocytic leukemia. Blood, 2014, 123, 875-883.	1.4	26

#	Article	IF	Citations
109	Detection of monoclonal T populations in patients with KIR-restricted chronic lymphoproliferative disorder of NK cells. Haematologica, 2014, 99, 1826-1833.	3.5	21
110	Cortactin, another player in the Lyn signaling pathway, is over-expressed and alternatively spliced in leukemic cells from patients with B-cell chronic lymphocytic leukemia. Haematologica, 2014, 99, 1069-1077.	3.5	32
111	Infections in Patients with Myelodysplastic Syndrome/Acute Myeloid Leukemia Treated with Azacitidine: Report from a Single Center. Blood, 2014, 124, 5622-5622.	1.4	13
112	Are T-LGL Leukemia and NK-Chronic Lymphoproliferative Disorder really two distinct diseases?. Translational Medicine @ UniSa, 2014, 8, 4-11.	0.5	14
113	Novel players in multiple myeloma pathogenesis: Role of protein kinases CK2 and GSK3. Leukemia Research, 2013, 37, 221-227.	0.8	28
114	Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity. Journal of Hematology and Oncology, 2013, 6, 78.	17.0	46
115	Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. MAbs, 2013, 5, 826-837.	5.2	105
116	EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukaemia. Leukemia Research, 2013, 37, 1457-1460.	0.8	11
117	Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia. American Journal of Hematology, 2013, 88, 277-282.	4.1	17
118	Clofazimine, Psora-4 and PAP-1, inhibitors of the potassium channel Kv1.3, as a new and selective therapeutic strategy in chronic lymphocytic leukemia. Leukemia, 2013, 27, 1782-1785.	7.2	75
119	Combination of Rituximab, Bendamustine, and Cytarabine for Patients With Mantle-Cell Non-Hodgkin Lymphoma Ineligible for Intensive Regimens or Autologous Transplantation. Journal of Clinical Oncology, 2013, 31, 1442-1449.	1.6	167
120	Bendamustine in chronic lymphocytic leukemia: Outcome according to different clinical and biological prognostic factors in the everyday clinical practice. American Journal of Hematology, 2013, 88, 955-960.	4.1	14
121	Intrinsic and extrinsic mechanisms contribute to maintain the JAK/STAT pathway aberrantly activated in T-type large granular lymphocyte leukemia. Blood, 2013, 121, 3843-3854.	1.4	85
122	Pancreatic Tumors and Immature Immunosuppressive Myeloid Cells in Blood and Spleen: Role of Inhibitory Co-Stimulatory Molecules PDL1 and CTLA4. An In Vivo and In Vitro Study. PLoS ONE, 2013, 8, e54824.	2.5	44
123	Protein Kinase CK2 Inhibition Down Modulates the NF-ÎºB and STAT3 Survival Pathways, Enhances the Cellular Proteotoxic Stress and Synergistically Boosts the Cytotoxic Effect of Bortezomib on Multiple Myeloma and Mantle Cell Lymphoma Cells. PLoS ONE, 2013, 8, e75280.	2.5	75
124	R-Vemp Is a Safe and Effective Chemo-Immunotherapeutic Regimen In Elderly Unfit DLBCL Patients: Report From a Single Center-Experience. Blood, 2013, 122, 3042-3042.	1.4	0
125	Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party. Annals of Oncology, 2012, 23, 1499-1502.	1.2	68
126	Protein Kinase CK2 Protects Multiple Myeloma Cells from ER Stressâ€“Induced Apoptosis and from the Cytotoxic Effect of HSP90 Inhibition through Regulation of the Unfolded Protein Response. Clinical Cancer Research, 2012, 18, 1888-1900.	7.0	71

#	Article	IF	Citations
127	S1P1 expression is controlled by the pro-oxidant activity of p66Shc and is impaired in B-CLL patients with unfavorable prognosis. Blood, 2012, 120, 4391-4399.	1.4	50
128	Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways. Leukemia, 2012, 26, 1174-1179.	7.2	94
129	HS1, a Lyn Kinase Substrate, Is Abnormally Expressed in B-Chronic Lymphocytic Leukemia and Correlates with Response to Fludarabine-Based Regimen. PLoS ONE, 2012, 7, e39902.	2.5	29
130	Telomere length and telomerase levels delineate subgroups of B-cell chronic lymphocytic leukemia with different biological characteristics and clinical outcomes. Haematologica, 2012, 97, 56-63.	3.5	47
131	State of the art in natural killer cell malignancies. International Journal of Laboratory Hematology, 2012, 34, 117-128.	1.3	23
132	Signalling Molecules as Selective Targets for Therapeutic Strategies in Multiple Myeloma. , 2012, , 87-108.		0
133	BRAFMutations in Hairy-Cell Leukemia. New England Journal of Medicine, 2011, 364, 2305-2315.	27.0	949
134	Lyn-mediated SHP-1 recruitment to CD5 contributes to resistance to apoptosis of B-cell chronic lymphocytic leukemia cells. Leukemia, 2011, 25, 1768-1781.	7.2	55
135	Pancreatic Cancer Alters Human CD4+ T Lymphocyte Function. Pancreas, 2011, 40, 1131-1137.	1.1	19
136	Serine-Threonine Protein Kinases CK1, CK2 and GSK3 in Normal and Malignant Haematopoiesis. Current Signal Transduction Therapy, 2011, 6, 88-98.	0.5	4
137	KIR/HLAâ€‐mismatching and risk of relapse in paediatric patients undergoing nonâ€‐haploidentical allogeneic haematopoietic stem cell transplantation. Pediatric Transplantation, 2011, 15, 198-204.	1.0	11
138	Successful control of Blastoschizomyces capitatus infection in three consecutive acute leukaemia patients despite initial unresponsiveness to liposomal amphotericin B. Mycoses, 2011, 54, 365-369.	4.0	4
139	Overexpression of HOXB7 and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocations. American Journal of Hematology, 2011, 86, E64-E66.	4.1	9
140	Serum vascular endothelial growth factor (VEGF) in the differential diagnosis of amyloid neuropathy and POEMS syndrome. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 106-108.	3.0	0
141	High-dose melphalan and autologous stem cell transplantation for AL amyloidosis: recent trends in treatment-related mortality and 1-year survival at a single institution. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 127-129.	3.0	6
142	Sarcoidosis is a Th1/Th17 multisystem disorder. Thorax, 2011, 66, 144-150.	5.6	247
143	Coexistence of primary AL amyloidosis and POEMS syndrome: Efficacy of melphalanâ€‐dexamethasone and role of biochemical markers in monitoring the diseases course. American Journal of Hematology, 2010, 85, 131-132.	4.1	11
144	Lack of expression of inhibitory KIR3DL1 receptor in patients with natural killer cell-type lymphoproliferative disease of granular lymphocytes. Haematologica, 2010, 95, 1722-1729.	3.5	24

#	Article	IF	Citations
145	Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death. BMC Cancer, 2010, 10, 526.	2.6	39
146	The Italian Society of Immunology: past, present and future. European Journal of Immunology, 2010, 40, 2664-2666.	2.9	1
147	3-(2,4-Dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione (SB216763), a Glycogen Synthase Kinase-3 Inhibitor, Displays Therapeutic Properties in a Mouse Model of Pulmonary Inflammation and Fibrosis. Journal of Pharmacology and Experimental Therapeutics, 2010, 332, 785-794.	2.5	36
148	Large granular lymphocyte disorders: new etiopathogenetic clues as a rationale for innovative therapeutic approaches. Haematologica, 2009, 94, 1341-1345.	3.5	36
149	Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts. European Journal of Haematology, 2009, 82, 93-105.	2.2	21
150	Analysis of NK cell/DC interaction in NK-type lymphoproliferative disease of granular lymphocytes (LDGL): role of DNAM-1 and NKp30. Experimental Hematology, 2009, 37, 1167-1175.	0.4	15
151	The Quality of Life of Children and Adolescents with X-Linked Agammaglobulinemia. Journal of Clinical Immunology, 2009, 29, 501-507.	3.8	34
152	P077 Adaptation and changes in quality of life in patients with myelodysplastic syndrome. Leukemia Research, 2009, 33, S103.	0.8	0
153	Modulation of ER Stress/Unfolded Protein Response (UPR) Pathways in Multiple Myeloma Cells by Inhibition of Hsp90 and Serine-Threonine Kinase CK2.. Blood, 2009, 114, 3840-3840.	1.4	0
154	Clinical spectrum of Î³Î´+ T cell LGL leukemia: Analysis of 20 cases. Leukemia Research, 2008, 32, 45-48.	0.8	65
155	T Cells in the Myenteric Plexus of Achalasia Patients Show a Skewed TCR Repertoire and React to HSV-1 Antigens. American Journal of Gastroenterology, 2008, 103, 1598-1609.	0.4	120
156	Geldanamycin-induced Lyn dissociation from aberrant Hsp90-stabilized cytosolic complex is an early event in apoptotic mechanisms in B-chronic lymphocytic leukemia. Blood, 2008, 112, 4665-4674.	1.4	53
157	Effects of CK2 Inhibition on Multiple Signaling Pathways in Myeloma Cells. Blood, 2008, 112, 5163-5163.	1.4	0
158	Right Atrial Mass in a Patient With T-Cell Chronic Lymphocytic Leukemia. Circulation, 2007, 116, e569-72.	1.6	2
159	Expression and role of CCR6/CCL20 chemokine axis in pulmonary sarcoidosis. Journal of Leukocyte Biology, 2007, 82, 946-955.	3.3	43
160	Expression of Receptor for Advanced Glycation End Products in Sarcoid Granulomas. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 498-506.	5.6	23
161	Changes of human B and B-1a peripheral blood lymphocytes with age. Hematology, 2007, 12, 337-341.	1.5	20
162	The mitochondrial effects of novel apoptogenic molecules generated by psoralen photolysis as a crucial mechanism in PUVA therapy. Blood, 2007, 109, 4988-4994.	1.4	30

#	Article	IF	Citations
163	Granuloma Formation. , 2007, , 87-100.		1
164	T-cell type lymphoproliferative disease of granular lymphocytes (LDGL) is equipped with a phenotypic pattern typical of effector cytotoxic cells. Leukemia Research, 2007, 31, 371-377.	0.8	14
165	Telomerase expression in B-cell chronic lymphocytic leukemia predicts survival and delineates subgroups of patients with the same igVH mutation status and different outcome. Leukemia, 2007, 21, 965-972.	7.2	57
166	Genotypic evaluation of killer immunoglobulin-like receptors in NK-type lymphoproliferative disease of granular lymphocytes. Leukemia, 2007, 21, 1060-1069.	7.2	40
167	Multiple myeloma plasma cells show different chemokine receptor profiles at sites of disease activity. British Journal of Haematology, 2007, 138, 594-602.	2.5	44
168	Towards a new age in the treatment of multiple myeloma. Annals of Hematology, 2007, 86, 159-172.	1.8	31
169	SYSTEMIC DISEASE | Sarcoidosis. , 2006, , 196-202.		0
170	Multiple myeloma cell survival relies on high activity of protein kinase CK2. Blood, 2006, 108, 1698-1707.	1.4	123
171	The Mitochondrial Effects of Small Organic Ligands of BCL-2. Journal of Biological Chemistry, 2006, 281, 10066-10072.	3.4	62
172	Global monitoring of influenza: potential contribution of national networks from a French perspective. Expert Review of Anti-Infective Therapy, 2006, 4, 387-393.	4.4	5
173	Chemokine receptor expression in EBV-associated lymphoproliferation in hu/SCID mice: implications for CXCL12/CXCR4 axis in lymphoma generation. Blood, 2005, 105, 931-939.	1.4	38
174	Phenotypic and functional analyses of dendritic cells in patients with lymphoproliferative disease of granular lymphocytes (LDGL). Blood, 2005, 106, 3926-3931.	1.4	30
175	Heterogeneous intracellular expression of B-cell receptor components in B-cell chronic lymphocytic leukaemia (B-CLL) cells and effects of CD79b gene transfer on surface immunoglobulin levels in a B-CLL-derived cell line. British Journal of Haematology, 2005, 130, 878-889.	2.5	11
176	CD40 activation of B-CLL cells is associated with augmented intracellular levels of CD79b and increased BCR expression in a subset of patients. Leukemia, 2005, 19, 1099-1101.	7.2	3
177	Role for CXCR6 and Its Ligand CXCL16 in the Pathogenesis of T-Cell Alveolitis in Sarcoidosis. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 1290-1298.	5.6	81
178	Pulmonary Complications in Patients with Hematological Disorders: Pathobiological Bases and Practical Approach. Seminars in Respiratory and Critical Care Medicine, 2005, 26, 439-444.	2.1	9
179	CXCR3/CXCL10 interactions in the development of hypersensitivity pneumonitis. Respiratory Research, 2005, 6, 20.	3.6	26
180	Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. Journal of Clinical Investigation, 2005, 115, 369-378.	8.2	192

#	Article	IF	Citations
181	Lymphocytic Aspects. Lung Biology in Health and Disease, 2005, , 79-96.	0.1	0
182	Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. Journal of Clinical Investigation, 2005, 115, 369-378.	8.2	117
183	ACCESS: A Case Control Etiologic Study of Sarcoidosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2005, 22, 83-6.	0.2	28
184	Impact Factor as Measure of Scientific Quality. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 1070-1071.	5.6	9
185	CCL19 and CXCL12 Trigger in Vitro Chemotaxis of Human Mantle Cell Lymphoma B Cells. Clinical Cancer Research, 2004, 10, 964-971.	7.0	64
186	T cells in the lung of patients with hypersensitivity pneumonitis accumulate in a clonal manner. Journal of Leukocyte Biology, 2004, 75, 798-804.	3.3	15
187	The raft marker GM1 identifies functional subsets of granular lymphocytes in patients with CD3+ lymphoproliferative disease of granular lymphocytes. Leukemia, 2004, 18, 771-776.	7.2	3
188	Molecular therapeutic approaches to acute myeloid leukemia: targeting aberrant chromatin dynamics and signal transduction. Expert Review of Anticancer Therapy, 2004, 4, 387-400.	2.4	6
189	Immunosuppressive therapy for idiopathic retroperitoneal fibrosis: a retrospective analysis of 26 cases. American Journal of Medicine, 2004, 116, 194-197.	1.5	138
190	Part II: Vaccines for haematological malignant disorders. Lancet Oncology, The, 2004, 5, 727-737.	10.7	37
191	New aspects of hypersensitivity pneumonitis. Current Opinion in Pulmonary Medicine, 2004, 10, 378-382.	2.6	53
192	Homeostatic chemokines drive migration of malignant B cells in patients with non-Hodgkin lymphomas. Blood, 2004, 104, 502-508.	1.4	144
193	The neutrophil-activating protein of Helicobacter pylori (HP-NAP) activates the MAPK pathway in human neutrophils. European Journal of Immunology, 2003, 33, 840-849.	2.9	48
194	Upregulation of CXCR1 by proliferating cells in patients with lymphoproliferative disease of granular lymphocytes. British Journal of Haematology, 2003, 120, 765-773.	2.5	9
195	Ifosfamide and Cyclophosphamide: Effects on Immunosurveillance. Oncology, 2003, 65, 17-20.	1.9	28
196	Aberrant Wnt/Î²-Catenin Pathway Activation in Idiopathic Pulmonary Fibrosis. American Journal of Pathology, 2003, 162, 1495-1502.	3.8	625
197	Natural killer receptors in patients with lymphoproliferative diseases of granular lymphocytes. Seminars in Hematology, 2003, 40, 201-212.	3.4	35
198	Expression and function of KIR and natural cytotoxicity receptors in NK-type lymphoproliferative diseases of granular lymphocytes. Blood, 2003, 102, 1797-1805.	1.4	106

#	Article	IF	Citations
199	Bronchiolar Epithelium in Idiopathic Pulmonary Fibrosis/Usual Interstitial Fibrosis. Lung Biology in Health and Disease, 2003, , 631-664.	0.1	0
200	Prognostic Factors in Malignant Transformation of Monoclonal Gammopathy of Undetermined Significance. Leukemia and Lymphoma, 2002, 43, 1713-1714.	1.3	0
201	Complement Receptor 1 Gene Polymorphisms in Sarcoidosis. American Journal of Respiratory Cell and Molecular Biology, 2002, 27, 17-23.	2.9	64
202	Applied clinical immunology in sarcoidosis. Current Opinion in Pulmonary Medicine, 2002, 8, 441-444.	2.6	20
203	T-lymphocytes and cytokines in sarcoidosis. Current Opinion in Pulmonary Medicine, 2002, 8, 435-440.	2.6	79
204	Why antiviral CD8 T lymphocytes fail to prevent progressive immunodeficiency in HIV-1 infection. Blood, 2002, 99, 1876-1878.	1.4	0
205	Abnormal Re-epithelialization and Lung Remodeling in Idiopathic Pulmonary Fibrosis: The Role of Î”N-p63. Laboratory Investigation, 2002, 82, 1335-1345.	3.7	200
206	Lymphocytes. , 2002, , 119-130.		0
207	CXCR3 and Its Ligand CXCL10 Are Expressed by Inflammatory Cells Infiltrating Lung Allografts and Mediate Chemotaxis of T Cells at Sites of Rejection. American Journal of Pathology, 2001, 158, 1703-1711.	3.8	195
208	Telomerase Activity and Clinical Progression in Chronic Lymphoproliferative Disorders of B-Cell Lineage. Leukemia and Lymphoma, 2001, 41, 35-45.	1.3	6
209	Alveolar macrophage-T cell interactions during Th1-type sarcoid inflammation. Microscopy Research and Technique, 2001, 53, 278-287.	2.2	35
210	Identification of NKp80, a novel triggering molecule expressed by human NK cells. European Journal of Immunology, 2001, 31, 233-242.	2.9	185
211	Antiapoptotic Effects of IL-15 on Pulmonary Tc1 Cells of Patients with Human Immunodeficiency Virus Infection. American Journal of Respiratory and Critical Care Medicine, 2001, 163, 484-489.	5.6	15
212	HLA-Gm/kappam interaction in sarcoidosis. Suggestions for a complex genetic structure. European Respiratory Journal, 2000, 16, 74-80.	6.7	12
213	New pathogenetic insights into the sarcoid granuloma. Current Opinion in Rheumatology, 2000, 12, 71-76.	4.3	128
214	B7 costimulatory molecules from malignant cells in patients with B-cell chronic lymphoproliferative disorders trigger T-cell proliferation. Cancer, 2000, 89, 1259-1268.	4.1	23
215	Clinicopathological features of aggressive large granular lymphocyte leukaemia resemble Fas ligand transgenic mice. British Journal of Haematology, 2000, 108, 717-723.	2.5	36
216	Immune mechanisms in interstitial lung diseases. Allergy: European Journal of Allergy and Clinical Immunology, 2000, 55, 1103-1120.	5.7	45

#	Article	IF	Citations
217	Analysis of TNF-receptor and ligand superfamily molecules in patients with lymphoproliferative disease of granular lymphocytes. Blood, 2000, 96, 647-654.	1.4	19
218	CXC Chemokines IP-10 and Mig Expression and Direct Migration of Pulmonary CD8 + /CXCR3 + T Cells in the Lungs of Patients with HIV Infection and T-Cell Alveolitis. American Journal of Respiratory and Critical Care Medicine, 2000, 162, 1466-1473.	5.6	95
219	Analysis of TNF-receptor and ligand superfamily molecules in patients with lymphoproliferative disease of granular lymphocytes. Blood, 2000, 96, 647-654.	1.4	7
220	B7 costimulatory molecules from malignant cells in patients with b-cell chronic lymphoproliferative disorders trigger t-cell proliferation. Cancer, 2000, 89, 1259-68.	4.1	2
221	Regulation of alveolar macrophage-T cell interactions during Th1-type sarcoid inflammatory process. American Journal of Physiology - Lung Cellular and Molecular Physiology, 1999, 277, L240-L250.	2.9	35
222	CD8 T-Cell Infiltration in Extravascular Tissues of Patients With Human Immunodeficiency Virus Infection. Interleukin-15 Upmodulates Costimulatory Pathways Involved in the Antigen-Presenting Cellsâ€"T-Cell Interaction. Blood, 1999, 93, 1277-1286.	1.4	25
223	Detection of identical T-cell clonotype expansions in both the donor and recipient after allogeneic bone marrow transplantation. British Journal of Haematology, 1999, 106, 119-127.	2.5	6
224	Telomerase activity in chronic lymphoproliferative disorders of B-cell lineage. British Journal of Haematology, 1999, 106, 662-668.	2.5	50
225	The growth and the control of human immunodeficiency virus in the lung: implications for highly active antiretroviral therapy. European Journal of Clinical Investigation, 1999, 29, 964-972.	3.4	22
226	The chemokine receptor CXCR3 is expressed on malignant B cells and mediates chemotaxis. Journal of Clinical Investigation, 1999, 104, 115-121.	8.2	134
227	CD8 T-Cell Infiltration in Extravascular Tissues of Patients With Human Immunodeficiency Virus Infection. Interleukin-15 Upmodulates Costimulatory Pathways Involved in the Antigen-Presenting Cellsâ€"T-Cell Interaction. Blood, 1999, 93, 1277-1286.	1.4	11
228	Antibodies to the IL-12 receptor beta 2 chain mark human Th1 but not Th2 cells in vitro and in vivo. Journal of Immunology, 1999, 162, 3926-32.	0.8	101
229	ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 1999, 16, 149-73.	0.2	736
230	CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies. Modern Pathology, 1999, 12, 1101-6.	5.5	85
231	Cells and molecules involved in the development of sarcoid granuloma. Journal of Clinical Immunology, 1998, 18, 184-192.	3.8	44
232	The activating form of CD94 receptor complex: CD94 covalently associated with the Kp39 protein that represents the product of the NKG2-C gene. European Journal of Immunology, 1998, 28, 327-338.	2.9	94
233	The Italian quality control study for evaluation of CD4 cells in centres involved in the treatment of HIV-1 patients. Clinical and Experimental Immunology, 1998, 111, 564-573.	2.6	10
234	HIV load in highly purified CD8+ T cells retrieved from pulmonary and blood compartments. Journal of Leukocyte Biology, 1998, 64, 298-301.	3.3	20

#	Article	IF	Citations
235	Cell apoptosis and granulomatous lung diseases. Current Opinion in Pulmonary Medicine, 1998, 4, 261-266.	2.6	23
236	Impaired cytokine production by neutrophils isolated from patients with AIDS. Aids, 1998, 12, 373-379.	2.2	25
237	Human Immunodeficiency Virus and the Lung. , 1998, , 141-165.		1
238	Cytokines in sarcoidosis. Seminars in Respiratory Infections, 1998, 13, 184-96.	1.3	33
239	Chemotactic cytokines: from the molecular level to clinical use. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 1998, 15, 131-3.	0.2	7
240	Large granular lymphocytosis. Haematologica, 1998, 83, 936-42.	3.5	31
241	Involvement of the IP-10 chemokine in sarcoid granulomatous reactions. Journal of Immunology, 1998, 161, 6413-20.	0.8	123
242	Release of prostaglandin E2 and leukotriene B4 by alveolar macrophages from patients with sarcoidosis. Thorax, 1997, 52, 76-83.	5.6	13
243	Role of Bronchoalveolar Lavage in Predicting Survival of Patients with Human Immunodeficiency Virus Infection. American Journal of Respiratory and Critical Care Medicine, 1997, 156, 1501-1507.	5.6	29
244	Selection of T lymphocytes bearing limited TCR-Vbeta regions in the lung of hypersensitivity pneumonitis and sarcoidosis.. American Journal of Respiratory and Critical Care Medicine, 1997, 155, 587-596.	5.6	34
245	Immune effector cells in idiopathic pulmonary fibrosis. Current Opinion in Pulmonary Medicine, 1997, 3, 348-355.	2.6	33
246	Interleukin-15: A Novel Cytokine with Regulatory Properties on Normal and Neoplastic B Lymphocytes. Leukemia and Lymphoma, 1997, 27, 35-42.	1.3	39
247	Immunological, clinical and molecular aspects of sarcoidosis. Molecular Aspects of Medicine, 1997, 18, 91-165.	6.4	22
248	The Lymphoproliferative Disease of Granular Lymphocytes: Updated Criteria for Diagnosis. Blood, 1997, 89, 256-260.	1.4	324
249	Interleukin-15 Triggers the Proliferation and Cytotoxicity of Granular Lymphocytes in Patients With Lymphoproliferative Disease of Granular Lymphocytes. Blood, 1997, 89, 201-211.	1.4	106
250	Interleukin-15 Triggers Activation and Growth of the CD8 T-Cell Pool in Extravascular Tissues of Patients With Acquired Immunodeficiency Syndrome. Blood, 1997, 90, 1115-1123.	1.4	51
251	Seroreactivity to an Envelope Protein of Human T-Cell Leukemia/Lymphoma Virus in Patients With CD3â˜ (Natural Killer) Lymphoproliferative Disease of Granular Lymphocytes. Blood, 1997, 90, 1977-1981.	1.4	55
252	Spontaneous resolution of p58/EB6 antigen restricted NKâ€type lymphoproliferative disease of granular lymphocytes: role of Epstein Barr virus infection. British Journal of Haematology, 1997, 99, 215-221.	2.5	14

#	Article	IF	Citations
253	Interleukin-15 Triggers the Proliferation and Cytotoxicity of Granular Lymphocytes in Patients With Lymphoproliferative Disease of Granular Lymphocytes. Blood, 1997, 89, 201-211.	1.4	8
254	Interleukin-15 Triggers Activation and Growth of the CD8 T-Cell Pool in Extravascular Tissues of Patients With Acquired Immunodeficiency Syndrome. Blood, 1997, 90, 1115-1123.	1.4	3
255	Interleukin-15 triggers the proliferation and cytotoxicity of granular lymphocytes in patients with lymphoproliferative disease of granular lymphocytes. Blood, 1997, 89, 201-11.	1.4	39
256	The lymphoproliferative disease of granular lymphocytes: updated criteria for diagnosis. Blood, 1997, 89, 256-60.	1.4	154
257	Bias toward use of T-cell receptor variable regions in the lung: research tool or clinically useful technique?. European Respiratory Journal, 1997, 10, 767-9.	6.7	3
258	Human killer cell activatory receptors for MHC class I molecules are included in a multimeric complex expressed by natural killer cells. Journal of Immunology, 1997, 158, 5083-6.	0.8	188
259	Seroreactivity to an envelope protein of human T-cell leukemia/lymphoma virus in patients with CD3- (natural killer) lymphoproliferative disease of granular lymphocytes. Blood, 1997, 90, 1977-81.	1.4	20
260	B lymphocytes from patients with chronic lymphoproliferative disorders are equipped with different costimulatory molecules. Cancer Research, 1997, 57, 4940-7.	0.9	72
261	IMMUNOLOGIC EFFECTS OF HIV IN THE LUNG. Clinics in Chest Medicine, 1996, 17, 633-645.	2.1	18
262	The natural killer-related receptor for HLA-C expressed on T cells from CD3+ lymphoproliferative disease of granular lymphocytes displays either inhibitory or stimulatory function. Blood, 1996, 87, 2369-2375.	1.4	31
263	Interleukin-15 promotes the growth of leukemic cells of patients with B- cell chronic lymphoproliferative disorders. Blood, 1996, 87, 3327-3335.	1.4	81
264	Skewing of the T-cell receptor repertoire in the lung of patients with HIV-1 infection. Aids, 1996, 10, 729-738.	2.2	21
265	Immunology of idopathic pulmonary fibrosis. Current Opinion in Pulmonary Medicine, 1996, 2, 364-369.	2.6	12
266	ILâ€12 is involved in the activation of CD3 + granular lymphocytes in patients with lymphoproliferative disease of granular lymphocytes. British Journal of Haematology, 1996, 92, 308-314.	2.5	9
267	A novel surface molecule homologous to the p58/p50 family of receptors is selectively expressed on a subset of human natural killer cells and induces both triggering of cell functions and proliferation. European Journal of Immunology, 1996, 26, 1816-1824.	2.9	126
268	Alterations in T cells of cancer-bearers: whence specificity?. Trends in Immunology, 1996, 17, 365-368.	7.5	57
269	HIV and pulmonary immune responses. Trends in Immunology, 1996, 17, 359-364.	7.5	34
270	Lysis of pulmonary fibroblasts by lymphokine (ILâ€2)â€activated killer cellsâ€"a mechanism affecting the human lung microenvironment?. Clinical and Experimental Immunology, 1996, 105, 383-388.	2.6	6

#	Article	IF	Citations
271	Cheese workers' lung. Allergy: European Journal of Allergy and Clinical Immunology, 1996, 51, 959-960.	5.7	10
272	Lung Lymphocytes: Origin, Biological Functions, and Laboratory Techniques for Their Study in immune-Mediated Pulmonary Disorders. Critical Reviews in Clinical Laboratory Sciences, 1996, 33, 423-455.	6.1	16
273	Polymorphism of angiotensin-converting enzyme gene in sarcoidosis.. American Journal of Respiratory and Critical Care Medicine, 1996, 153, 851-854.	5.6	70
274	Expression of tumor necrosis factor-receptor superfamily members by lung T lymphocytes in interstitial lung disease.. American Journal of Respiratory and Critical Care Medicine, 1996, 153, 1359-1367.	5.6	63
275	Detection of Epstein-Barr Virus by PCR Analyses in Lymphoproliferative Disease of Granular Lymphocytes. Leukemia and Lymphoma, 1996, 23, 371-374.	1.3	16
276	Role of IL-15, IL-2, and their receptors in the development of T cell alveolitis in pulmonary sarcoidosis. Journal of Immunology, 1996, 157, 910-8.	0.8	115
277	The CD5/CD72 receptor system is coexpressed with several functionally relevant counterstructures on human B cells and delivers a critical signaling activity. Journal of Immunology, 1996, 157, 1854-62.	0.8	44
278	Alveolar macrophages as a cell source of cytokine hyperproduction in HIV-related interstitial lung disease. Journal of Leukocyte Biology, 1995, 58, 495-500.	3.3	31
279	Tumour-infiltrating lymphocytes bear the 75 kDa tumour necrosis factor receptor. British Journal of Cancer, 1995, 71, 240-245.	6.4	17
280	"The sarcoidosis map": a joint survey of clinical and immunogenetic findings in two European countries.. American Journal of Respiratory and Critical Care Medicine, 1995, 152, 557-564.	5.6	149
281	CD8+ T lymphocytes in the lung of acquired immunodeficiency syndrome patients harbor human immunodeficiency virus type 1. Blood, 1995, 85, 2308-2314.	1.4	67
282	Expression of TNF receptors by T cells and membrane TNF-alpha by alveolar macrophages suggests a role for TNF-alpha in the regulation of the local immune responses in the lung of HIV-1-infected patients. Journal of Immunology, 1995, 154, 2928-38.	0.8	24
283	Analysis of the T cell receptor in the lymphoproliferative disease of granular lymphocytes: superantigen activation of clonal CD3+ granular lymphocytes. Cancer Research, 1995, 55, 6140-5.	0.9	45
284	Expression and regulation of tumor necrosis factor, interleukin-2, and hematopoietic growth factor receptors in B-cell chronic lymphocytic leukemia. Blood, 1994, 84, 4249-4256.	1.4	50
285	Does analysis of bronchoalveolar lavage fluid provide a tool to monitor disease progression or to predict survival in patients with HIV-1 infection?. Thorax, 1994, 49, 848-851.	5.6	12
286	Elevated IL-8 and MCP-1 in the bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis.. American Journal of Respiratory and Critical Care Medicine, 1994, 149, 655-659.	5.6	239
287	Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells. Cancer, 1994, 74, 2562-2569.	4.1	6
288	Circulating soluble adhesion molecules: more observations on ICAM-1 in patients with Hodgkin's disease. Trends in Immunology, 1994, 15, 140-141.	7.5	4

#	Article	IF	Citations
289	Î³Î´ T Cell Receptor Subsets in the Lung of Patients with HIV-1 Infection. Cellular Immunology, 1994, 153, 194-205.	3.0	27
290	Serum levels of tumour necrosis factor-Î± in patients with B-cell chronic lymphocytic leukaemia. European Journal of Cancer, 1994, 30, 1259-1263.	2.8	43
291	Functional role of IL-2 receptors on tumour-infiltrating lymphocytes. British Journal of Cancer, 1994, 69, 1046-1051.	6.4	12
292	High serum level of the soluble form of CD30 molecule in the early phase of HIV-1 infection as an independent predictor of progression to AIDS. Aids, 1994, 8, 741-746.	2.2	118
293	Expression and regulation of tumor necrosis factor, interleukin-2, and hematopoietic growth factor receptors in B-cell chronic lymphocytic leukemia. Blood, 1994, 84, 4249-56.	1.4	9
294	Serum levels of soluble interleukin-2 receptor in Hodgkin disease. Relationship with clinical stage, tumor burden, and treatment outcome. Cancer, 1993, 72, 201-206.	4.1	38
295	ICAM-1 tissue overexpression associated with increased serum levels of its soluble form in Hodgkin's disease. British Journal of Haematology, 1993, 84, 161-162.	2.5	41
296	Soluble interleukin-2 receptor in hairy-cell leukemia: a reliable marker of disease. International Journal of Clinical and Laboratory Research, 1993, 23, 34-37.	1.0	11
297	CD8 alveolitis in sarcoidosis: Incidence, phenotypic characteristics, and clinical features. American Journal of Medicine, 1993, 95, 466-472.	1.5	46
298	HIV-1 and the Lung: Infectivity, Pathogenic Mechanisms, and Cellular Immune Responses Taking Place in the Lower Respiratory Tract. The American Review of Respiratory Disease, 1993, 147, 1038-1049.	2.9	88
299	Alveolar Macrophages in HIV-1 Infection Express Accessory Molecules, Activation Markers, and Release Increased Biological Response Modifiers. Chest, 1993, 103, 108S-111S.	0.8	10
300	Cellular Immunity in Sarcoidosis and Hypersensitivity Pneumonitis. Chest, 1993, 103, 139S-143S.	0.8	6
301	CD5+ Leukemic Monocytoid B-cell Lymphoma and Lymphocytic Lymphomas. American Journal of Clinical Pathology, 1993, 100, 187-188.	0.7	2
302	HLA Class I, II, and III Polymorphism in Italian Patients With Sarcoidosis. Chest, 1993, 104, 1170-1175.	0.8	39
303	Failure to detect Epstein-Barr virus DNA in peripheral blood mononuclear cells of most patients with large granular lymphocyte leukemia. Blood, 1993, 81, 2723-2727.	1.4	45
304	Phenotypic diversity of natural killer (NK) populations in patients with NK-type lymphoproliferative disease of granular lymphocytes. Blood, 1993, 81, 2381-2385.	1.4	55
305	Expression and functional role of tumor necrosis factor receptors on leukemic cells from patients with type B chronic lymphoproliferative disorders. Blood, 1993, 81, 752-758.	1.4	50
306	Clonal studies of CD3- lymphoproliferative disease of granular lymphocytes. Blood, 1993, 81, 2363-2368.	1.4	63

#	Article	IF	Citations
307	Failure to detect Epstein-Barr virus DNA in peripheral blood mononuclear cells of most patients with large granular lymphocyte leukemia. Blood, 1993, 81, 2723-2727.	1.4	1
308	Alveolar macrophages in HIV-1 infection express accessory molecules, activation markers, and release increased biological response modifiers. Chest, 1993, 103, 108S-111.	0.8	0
309	Clonal studies of CD3- lymphoproliferative disease of granular lymphocytes. Blood, 1993, 81, 2363-2368.	1.4	0
310	Constitutive expression of tenascin in T-dependent zones of human lymphoid tissues. American Journal of Pathology, 1993, 143, 1348-55.	3.8	42
311	Synthesis and release of granulocyte–macrophage colony–stimulating factor by alveolar macrophages of patients with sarcoidosis. Sarcoidosis, 1993, 10, 147-8.	0.4	8
312	Immunohistochemical detection of microenvironmental abnormalities in lung biopsies from patients with sarcoidosis. Sarcoidosis, 1993, 10, 152-3.	0.4	1
313	Pulmonary immune cells in health and disease: lymphocytes. European Respiratory Journal, 1993, 6, 1378-401.	6.7	44
314	Failure to detect Epstein-Barr virus DNA in peripheral blood mononuclear cells of most patients with large granular lymphocyte leukemia. Blood, 1993, 81, 2723-7.	1.4	10
315	Human retroviruses and their aetiological link to pulmonary diseases. European Respiratory Journal, 1993, 6, 925-9.	6.7	5
316	Phenotypic diversity of natural killer (NK) populations in patients with NK-type lymphoproliferative disease of granular lymphocytes. Blood, 1993, 81, 2381-5.	1.4	9
317	High Serum Levels of Soluble Interleukin-2 Receptor and Absence of Detectable Levels of Soluble CD30 Molecule: A Specific Diagnostic Combination for Hairy Cell Leukemia. Leukemia and Lymphoma, 1992, 6, 385-388.	1.3	2
318	Immunology of Extrapulmonary Sarcoid Lesions. Seminars in Respiratory and Critical Care Medicine, 1992, 13, 380-392.	2.1	0
319	Spontaneous Production of Interleukin-6 by Alveolar Macrophages from Human Immunodeficiency Virus Type 1-Infected Patients. Journal of Infectious Diseases, 1992, 166, 731-737.	4.0	63
320	Prognostic significance of soluble CD8 serum levels in HIV-1 infection. Aids, 1992, 6, 133.	2.2	3
321	Determinants of HIV disease progression. Lancet, The, 1992, 339, 130.	13.7	2
322	Role of tumor necrosis factor-alpha and its specific 55-Kd and 75-Kd receptors in patients with lymphoproliferative disease of granular lymphocytes. Blood, 1992, 80, 2030-2037.	1.4	18
323	Expression of a functional p75 interleukin-2 receptor on lung lymphocytes from patients with human immunodeficiency virus type 1 (HIV-1) infection. Journal of Clinical Immunology, 1992, 12, 371-380.	3.8	9
324	Highly concentrated urine-purified Tac peptide fails to inhibit IL-2-dependent cell proliferation in vitro. Cellular Immunology, 1992, 141, 253-259.	3.0	12

#	Article	IF	Citations
325	The interleukin-2/interleukin-2 receptor system: structural, immunological, and clinical features. International Journal of Clinical and Laboratory Research, 1992, 22, 133-142.	1.0	17
326	Cytotoxic In vitro function in patients with metastatic renal cell carcinoma before and after alpha-2b-interferon therapy effects of activation with recombinant interleukin-2. Cancer, 1992, 69, 2525-2531.	4.1	6
327	Transbronchial biopsy in sarcoidosis: the role of immunohistochemical analysis for granuloma detection. Sarcoidosis, 1992, 9, 95-100.	0.4	6
328	Expression and functional role of the p75 interleukin 2 receptor chain on leukemic hairy cells. Cancer Research, 1992, 52, 5223-8.	0.9	11
329	Release of granulocyte-macrophage colony-stimulating factor by alveolar macrophages in the lung of HIV-1-infected patients. A mechanism accounting for macrophage and neutrophil accumulation. Journal of Immunology, 1992, 149, 3379-85.	0.8	35
330	Clonally expanded CD3+, CD4â^', CD8â^' cells bearing the or the T-cell receptor in patients with the lymphoproliferative disease of granular lymphocytes. Clinical Immunology and Immunopathology, 1991, 60, 371-383.	2.0	10
331	Serum interleukin-2 receptor as index of tumor burden in hairy cell leukemia [letter; comment]. Blood, 1991, 77, 2540-2542.	1.4	6
332	B-ly-7, a monoclonal antibody labeling of activated lung lymphocytes [letter]. Blood, 1991, 77, 1855-1856.	1.4	3
333	Prognostic Significance of the Evaluation of Bronchoalveolar Lavage Cell Populations in Patients with HIV-1 Infection and Pulmonary Involvement. Chest, 1991, 100, 1601-1606.	0.8	41
334	Shedding of the soluble form of the CD8 complex by CD8 +/HLA-DR + cells in HIV-1-infected patients. Aids, 1991, 5, 813-820.	2.2	15
335	Alveolar Macrophages from Patients with AIDS and AIDS-related Complex Constitutively Synthesize and Release Tumor Necrosis Factor Alpha. The American Review of Respiratory Disease, 1991, 144, 195-201.	2.9	51
336	Immunohistochemical characterization of sarcoid granuloma: differentiation antigens and adhesion molecules. Sarcoidosis, 1991, 8, 171-2.	0.4	5
337	Immunology of interstitial lung diseases: cellular events taking place in the lung of sarcoidosis, hypersensitivity pneumonitis and HIV infection. European Respiratory Journal, 1991, 4, 94-102.	6.7	54
338	Serum interleukin-2 receptor as index of tumor burden in hairy cell leukemia. Blood, 1991, 77, 2540-2.	1.4	2
339	Tumour necrosis factor: a cytokine with multiple biological activities. British Journal of Cancer, 1990, 61, 354-361.	6.4	97
340	Immune responses in the lung: Basic principles. Lung, 1990, 168, 1001-1012.	3.3	10
341	Bronchoalveolar lavage and the immunology of lung cancer. Lung, 1990, 168, 1041-1049.	3.3	10
342	Immunopathology of ocular sarcoidosis. International Ophthalmology, 1990, 14, 1-11.	1.4	8

#	Article	IF	Citations
343	Degradation of immobilized soluble elastin by tumor cells in culture: Quantitation by elisa. International Journal of Cancer, 1990, 46, 552-558.	5.1	6
344	Clinical course and prognosis of the lymphoproliferative disease of granular lymphocytes. A multicenter study. Cancer, 1990, 65, 341-348.	4.1	161
345	Mechanisms accounting for the defective natural killer activity in patients with hairy cell leukemia. Blood, 1990, 75, 1525-1530.	1.4	35
346	Cell membrane expression and functional role of the p75 subunit of interleukin-2 receptor in lymphoproliferative disease of granular lymphocytes. Blood, 1990, 76, 2080-2085.	1.4	34
347	Multimarker immunohistochemical staining of calgranulins, chloroacetate esterase, and S100 for simultaneous demonstration of inflammatory cells on paraffin sections.. Journal of Histochemistry and Cytochemistry, 1990, 38, 1669-1675.	2.5	34
348	Cytotoxic Events Taking Place in the Lung of Patients with HIV-1 Infection: Evidence of an Intrinsic Defect of the Major Histocompatibility Complex-unrestricted Killing Partially Restored by the Incubation with rIL-2. The American Review of Respiratory Disease, 1990, 142, 516-522.	2.9	22
349	Cell membrane expression and functional role of the p75 subunit of interleukin-2 receptor in lymphoproliferative disease of granular lymphocytes. Blood, 1990, 76, 2080-5.	1.4	8
350	The clinical use of BAL in patients with pulmonary infections. European Respiratory Journal, 1990, 3, 954-5, 961-9.	6.7	2
351	Mechanisms accounting for the defective natural killer activity in patients with hairy cell leukemia. Blood, 1990, 75, 1525-30.	1.4	5
352	Cellular immune responses in the lung of hypersensitivity pneumonitis. European Respiratory Journal, 1990, 3, 357-9.	6.7	5
353	Human Retroviruses and Lung Involvement. The American Review of Respiratory Disease, 1989, 139, 1317-1322.	2.9	28
354	Serum levels of soluble interleukin-2 receptors in acute and chronic viral hepatitis. Digestive Diseases and Sciences, 1989, 34, 1559-1563.	2.3	23
355	Release of natural killer cytotoxic factor in patients with lymphoproliferative disease of granular lymphocytes. Leukemia Research, 1989, 13, 315-322.	0.8	6
356	Hairy cell sensitivity to the lysis in vitro. Cancer Immunology, Immunotherapy, 1989, 30, 254-256.	4.2	2
357	Serum levels of soluble interleukin-2 receptor in hairy cell leukaemia: a reliable marker of neoplastic bulk. British Journal of Haematology, 1989, 73, 181-186.	2.5	31
358	Functional analysis of cytotoxic cells in patients with acute nonlymphoblastic leukemia in complete remission. Cancer, 1989, 64, 667-672.	4.1	16
359	Evaluation of serum levels of soluble interleukin-2 receptor in patients with chronic lymphoproliferative disorders of T-lymphocytes. Cancer, 1989, 64, 2019-2023.	4.1	15
360	Lymphoproliferative disease of granular lymphocytes in a patient with concomitant hepatitis B virus infection of CD4 lymphocytes. Journal of Clinical Immunology, 1989, 9, 401-408.	3.8	8

#	Article	IF	Citations
361	Serum levels of soluble CD8 are increased in patients with B chronic lymphocytic leukemia. European Journal of Cancer & Clinical Oncology, 1989, 25, 1577-1581.	0.7	5
362	Increased levels of soluble CD8 molecule in the serum of patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related disorders. Clinical Immunology and Immunopathology, 1989, 50, 146-153.	2.0	27
363	Increased Levels of Soluble Interleukin-2 Receptor in Non-Hodgkinâ€™s Lymphomas: Relationship with Clinical, Histologic, and Phenotypic Features. American Journal of Clinical Pathology, 1989, 92, 186-191.	0.7	48
364	Pulmonary alveolar macrophages from patients with active sarcoidosis express type IV collagenolytic proteinase. An enzymatic mechanism for influx of mononuclear phagocytes at sites of disease activity.. Journal of Clinical Investigation, 1989, 84, 605-612.	8.2	29
365	Generation of superoxide anion by alveolar macrophages in sarcoidosis: evidence for the activation of the oxygen metabolism in patients with high-intensity alveolitis. Immunology, 1989, 66, 451-8.	4.4	25
366	Increased serum levels of soluble interleukin-2 receptor in patients with systemic lupus erythematosus and rheumatoid arthritis. Journal of Clinical Immunology, 1988, 8, 447-452.	3.8	71
367	Natural killer cell function and lymphoid subpopulations in acute non-lymphoblastic leukaemia in complete remission. British Journal of Cancer, 1988, 58, 368-372.	6.4	42
368	Longitudinal study of alveolitis in hypersensitivity pneumonitis patients: An immunologic evaluation. Journal of Allergy and Clinical Immunology, 1988, 82, 577-585.	2.9	54
369	Different Types of Cytotoxic Lymphocytes Recovered from the Lungs of Patients with Hypersensitivity Pneumonitis. The American Review of Respiratory Disease, 1988, 137, 70-74.	2.9	58
370	Phenotypical and Functional Analysis of Bronchoalveolar Lavage Lymphocytes in Patients with HIV Infection. The American Review of Respiratory Disease, 1988, 138, 1609-1615.	2.9	71
371	Current Concepts on Bronchoalveolar Lavage Cells in Extrinsic Allergic Alveolitis. Respiration, 1988, 54, 59-65.	2.6	7
372	Origin of the soluble interleukin-2 receptor in the serum of patients with hairy cell leukemia. Leukemia, 1988, 2, 788-92.	7.2	18
373	Soluble interleukin-2 receptors in the serum of patients with Hodgkin's disease. British Journal of Cancer, 1987, 55, 427-428.	6.4	106
374	HTLV-I ANTIBODIES AND LYMPHOPROLIFERATIVE DISEASE OF GRANULAR LYMPHOCYTES. Lancet, The, 1987, 330, 1527.	13.7	20
375	High serum levels of soluble interleukin 2 receptor in patients with B chronic lymphocytic leukemia. Blood, 1987, 70, 396-400.	1.4	109
376	Pulmonary alveolar macrophages in patients with sarcoidosis and hypersensitivity pneumonitis: Characterization by monoclonal antibodies. Journal of Clinical Immunology, 1987, 7, 64-70.	3.8	36
377	Immunologic abnormalities in angioimmunoblastic lymphadenopathy. Cancer, 1987, 60, 2412-2418.	4.1	25
378	The lymphoproliferative disease of granular lymphocytes. A heterogeneous disorder ranging from indolent to aggressive conditions. Cancer, 1987, 60, 2971-2978.	4.1	179

#	Article	IF	Citations
379	Alpha-interferon activated cytotoxic lymphocytes in hairy cell leukemia patients: Evaluation of cytotoxic events. Leukemia Research, 1987, 11, 843-847.	0.8	13
380	Rearrangement for the T-cell receptor gene and co-expression of immature T-cell markers and natural killer cell phenotype, in a patient with acute lymphoblastic leukaemia. British Journal of Haematology, 1987, 65, 17-22.	2.5	8
381	THE SOLUBLE INTERLEUKIN-2 RECEPTOR IN HAEMATOLOGICAL DISORDERS. British Journal of Haematology, 1987, 67, 377-380.	2.5	69
382	Soluble interleukin-2 receptors in the sera of patients with hairy cell leukemia: relationship with the effect of recombinant alpha-interferon therapy on clinical parameters and natural killer in vitro activity. Blood, 1987, 70, 1530-1535.	1.4	95
383	Cytotoxic in vitro function in the lymphoproliferative disease of granular lymphocytes. Clinical and Experimental Immunology, 1987, 70, 222-30.	2.6	4
384	High serum levels of soluble interleukin-2 receptors in sarcoidosis. Sarcoidosis, 1987, 4, 25-7.	0.4	26
385	High serum levels of soluble interleukin 2 receptor in patients with B chronic lymphocytic leukemia. Blood, 1987, 70, 396-400.	1.4	28
386	Soluble interleukin-2 receptors in the sera of patients with hairy cell leukemia: relationship with the effect of recombinant alpha-interferon therapy on clinical parameters and natural killer in vitro activity. Blood, 1987, 70, 1530-5.	1.4	18
387	Increased levels of soluble interleukin-2 receptor in the serum of patients with human immunodeficiency virus infection. Diagnostic and Clinical Immunology, 1987, 5, 180-3.	0.3	6
388	Activated T Cells with Immunoregulatory Functions at Different Sites of Involvement in Sarcoidosis.. Annals of the New York Academy of Sciences, 1986, 465, 56-73.	3.8	45
389	Alpha-interferon activates the natural killer system in patients with hairy cell leukemia. Blood, 1986, 68, 293-296.	1.4	66
390	Detection of a Soluble form of the Receptor for Interleukin 2 in the Serum of Patients with Hairy Cell Leukaemia. International Journal of Biological Markers, 1986, 1, 101-104.	1.8	36
391	Immunoregulation in Farmer's Lung Disease. Chest, 1986, 89, 133S-135S.	0.8	4
392	Definition by CB12 monoclonal antibody of a differentiation marker specific for human monocytes and their bone marrow precursors. Cellular Immunology, 1986, 97, 276-285.	3.0	9
393	The Immunology of Sarcoidosis. Seminars in Respiratory and Critical Care Medicine, 1986, 8, 17-29.	2.1	12
394	Transient expression of type IV collagenolytic metalloproteinase by human mononuclear phagocytes.. Journal of Biological Chemistry, 1986, 261, 2369-2375.	3.4	107
395	Lung T cells in hypersensitivity pneumonitis: phenotypic and functional analyses. Journal of Immunology, 1986, 137, 1164-72.	0.8	59
396	Transient expression of type IV collagenolytic metalloproteinase by human mononuclear phagocytes. Journal of Biological Chemistry, 1986, 261, 2369-75.	3.4	96

#	Article	IF	Citations
397	Detection of a soluble form of the receptor for interleukin 2 in the serum of patients with hairy cell leukaemia. International Journal of Biological Markers, 1986, 1, 101-4.	1.8	14
398	Alpha-interferon activates the natural killer system in patients with hairy cell leukemia. Blood, 1986, 68, 293-6.	1.4	6
399	Impaired Gamma Interferon Production by Cells from Patients with Lymphoproliferative Disorders of Mature T and NK Cells. Scandinavian Journal of Immunology, 1985, 21, 315-320.	2.7	5
400	CHRONIC LYMPHOCYTOSIS DUE TO THE EXPANSION OF GRANULAR LYMPHOCYTES. British Journal of Haematology, 1985, 60, 771-773.	2.5	11
401	Phorbol ester induces abnormal chronic lymphocytic leukemia cells to express features of hairy cell leukemia. Blood, 1985, 66, 1035-1042.	1.4	57
402	Cultured T Cells from Patients with T Cell Chronic Lymphocytic Leukemia Demonstrate a Normal Phenotype. Immunobiology, 1985, 169, 186-197.	1.9	1
403	Immunohistologic analysis of a human pulmonary alveolar macrophage antigen. Clinical Immunology and Immunopathology, 1985, 37, 213-219.	2.0	15
404	Phenotypical and functional analysis of natural killer cells in sarcoidosis. Clinical Immunology and Immunopathology, 1985, 37, 262-275.	2.0	19
405	T-HELPER PHENOTYPE CHRONIC LYMPHOCYTIC LEUKAEMIA AND "ADULT T-CELL LEUKAEMIA" IN ITALY. Lancet, The, 1985, 326, 633-636.	13.7	38
406	T-HELPER PHENOTYPE LEUKAEMIAS: ROLE OF HTLV-I. Lancet, The, 1985, 326, 1367-1368.	13.7	6
407	Conjunctival Biopsy in Sarcoidosis. American Journal of Ophthalmology, 1985, 100, 347-348.	3.3	1
408	Bronchoalveolar lavage and lung histology. Comparative analysis of inflammatory and immunocompetent cells in patients with sarcoidosis and hypersensitivity pneumonitis. The American Review of Respiratory Disease, 1985, 132, 400-4.	2.9	97
409	Heterogeneous Expression of Dipeptidyl-Amino-Peptidase (DAP IV) in T-Cell Chronic Lymphocytic Leukemia. Acta Haematologica, 1984, 71, 277-281.	1.4	9
410	Abnormal expansions of polyclonal large to small size granular lymphocytes: reactive or neoplastic process?. Blood, 1984, 63, 1271-1277.	1.4	62
411	Immunohistological analysis of Tac antigen expression in tissues involved by Hodgkin's disease. British Journal of Cancer, 1984, 50, 415-417.	6.4	49
412	Chromosome studies in patients with T-CLL chronic lymphocytic leukemia and expansions of granular lymphocytes. International Journal of Cancer, 1984, 34, 171-176.	5.1	25
413	Characterization of two patients with lymphomas of large granular lymphocytes. Cancer, 1984, 53, 445-452.	4.1	39
414	Non-T, non-B childhood acute lymphoblastic leukemia. Correlation between cytochemical markers and first complete remission. Cancer, 1984, 54, 981-985.	4.1	6

#	Article	IF	Citations
415	Classification of patients with T-cell chronic lymphocytic leukemia and expansions of granular lymphocytes: Heterogeneity of Italian cases by a multiparameter analysis. Journal of Clinical Immunology, 1984, 4, 174-184.	3.8	24
416	B cells in chronic lymphocytic leukaemia comparative analysis of blood and bone marrow. Blut, 1984, 49, 69-73.	1.2	3
417	Immunohistological study in sarcoidosis: Evaluation at different sites of disease activity. Clinical Immunology and Immunopathology, 1984, 30, 29-40.	2.0	59
418	Distribution and heterogeneity of cells detected by HNK-1 monoclonal antibody in blood and tissues in normal, reactive and neoplastic conditions. Clinical and Experimental Immunology, 1984, 57, 195-206.	2.6	46
419	Evidence of cells bearing interleukin-2 receptor at sites of disease activity in sarcoid patients. Clinical and Experimental Immunology, 1984, 57, 331-7.	2.6	49
420	T cell subpopulations in B cell chronic lymphocytic leukaemias. Clinical and Experimental Immunology, 1984, 57, 752-4.	2.6	2
421	The immunological approach to the enigma of sarcoidosis. Sarcoidosis, 1984, 1, 24-35.	0.4	7
422	Abnormal expansions of polyclonal large to small size granular lymphocytes: reactive or neoplastic process?. Blood, 1984, 63, 1271-7.	1.4	9
423	T lymphocytes in B-cell chronic lymphocytic leukemia: Characterization by monoclonal antibodies and correlation with Fc receptors. Clinical Immunology and Immunopathology, 1983, 26, 155-161.	2.0	39
424	Immunohistologic study of bone marrow involvement in B-chronic lymphocytic leukemia. Blood, 1983, 62, 1289-1296.	1.4	78
425	HNK-1 monoclonal antibody (Leu-7) in the identification of abnormal expansions of large granular lymphocytes. Clinical and Experimental Immunology, 1983, 52, 641-7.	2.6	25
426	Immunohistologic study of bone marrow involvement in B-chronic lymphocytic leukemia. Blood, 1983, 62, 1289-96.	1.4	19
427	Redistribution of T Lymphocytes in the Lymph Nodes of Patients with Sarcoidosis. New England Journal of Medicine, 1982, 306, 48-49.	27.0	79
428	T-CELL LEUKAEMIA-LYMPHOMA VIRUS AND HETEROGENEITY OF CHRONIC T-CELL MALIGNANCIES. Lancet, The, 1982, 320, 1273.	13.7	11
429	Heterogeneity of T-CLL defined by monoclonal antibodies in nine patients. Clinical Immunology and Immunopathology, 1982, 24, 330-341.	2.0	29
430	Immunologic evaluation of T chronic lymphocyte leukemia cells: correlations among phenotype, functional activities, and morphology. Blood, 1982, 59, 688-695.	1.4	78
431	Chronic T-cell leukaemias. III. T-colonies, PHA response and correlation with membrane phenotype. Leukemia Research, 1982, 6, 809-814.	0.8	11
432	Binding of sheep erythrocytes in chronic lymphocytic leukemias of B-cell origin. Journal of Clinical Immunology, 1982, 2, 296-302.	3.8	8

#	Article	IF	Citations
433	Immunologic evaluation of T chronic lymphocyte leukemia cells: correlations among phenotype, functional activities, and morphology. Blood, 1982, 59, 688-95.	1.4	10
434	Immunoregulation in sarcoidosis. Clinical Immunology and Immunopathology, 1981, 19, 416-427.	2.0	25
435	N-Acetyl-Î²-D-Glucosaminidase Activity in T Chronic Lymphocytic Leukaemia. Acta Haematologica, 1981, 66, 69-70.	1.4	3
436	T-lymphocyte subpopulations in chronic lymphocytic leukemia: A quantitative and functional study. Cancer, 1981, 48, 2191-2197.	4.1	42
437	Cytochemical Study of Thymocytes and T Lymphocytes. British Journal of Haematology, 1980, 44, 577-582.	2.5	73
438	D cells with cytotoxic activity in acute lymphoblastic leukemia. Clinical Immunology and Immunopathology, 1980, 16, 238-244.	2.0	6
439	Immunological features in chronic lymphocytic leukaemia (CLL) of T cell origin. Journal of Clinical & Laboratory Immunology, 1979, 2, 45-50.	0.1	2
440	Stimulation induced by autologous lymphocyte subpopulations from healthy subjects in mixed lymphocyte reaction (MLR). Transplantation Proceedings, 1979, 11, 1373-4.	0.6	2